Noteworthy Stock to Watch For: Seattle Genetics, Inc. (SGEN)

Saturday, 13 Jan, 2018

Seattle Genetics's revenue was up 27.3% on a year-over-year basis. sell-side analysts anticipate that Seattle Genetics will post -0.93 earnings per share for the current year. The stock decreased 0.39% or $0.3 during the last trading session, reaching $77.31.

Lagoda Investment Management Lp decreased its stake in Seattle Genetics Inc (SGEN) by 23.04% based on its latest 2017Q3 regulatory filing with the SEC.

Seattle Genetics, Inc. has a consensus outperform rating from 16 Wall Street analysts, and the number of shares now sold short amount to at least 9.01% of shares outstanding. University Of Notre Dame Du Lac who had been investing in Seattle Genetics Inc for a number of months, seems to be bullish on the $7.54B market cap company. About 273,894 shares traded. 2017, Seattle Genetics, Inc. They set an outperform rating and a $58.00 price target on the stock. It also increased its holding in Alamos Gold Inc New Com by 6,938 shares in the quarter, for a total of 70,051 shares, and has risen its stake in Transmontaigne Partners LP Com (NYSE:TLP). There were 60 sold out positions, on the other hand, totaling 2,751,720 shares.

Among 2 analysts covering K12 (NYSE:LRN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 52% are positive. AO Smith Corp had 31 analyst reports since September 11, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with "Hold" rating in Tuesday, August 8 report. The rating was downgraded by Boenning & Scattergood to "Neutral" on Wednesday, October 25. Raymond James maintained it with "Outperform" rating and $24 target in Thursday, July 27 report. Blair William And Il reported 50,748 shares. The firm earned "Sector Weight" rating on Friday, April 28 by KeyBanc Capital Markets. (NYSE:LRN) has "Overweight" rating given on Wednesday, August 10 by First Analysis.

Since August 15, 2017, it had 0 buys, and 13 selling transactions for $2.88 million activity. $1.32M worth of stock was sold by Martineau Peter R on Tuesday, October 31. Commonwealth Equity Ser Inc has invested 0% in Seattle Genetics, Inc.

Investors sentiment increased to 1.14 in Q3 2017.

Since January 1, 0001, it had 0 insider purchases, and 17 sales for $9.99 million activity. It dropped, as 87 investors sold NKE shares while 457 reduced holdings. 12 funds opened positions while 23 raised stakes. 123.32 million shares or 19.18% less from 152.59 million shares in 2017Q2 were reported. Sumitomo Mitsui Holding accumulated 280,692 shares or 0.02% of the stock. Rothschild Invest Corp Il holds 0.09% in NIKE, Inc. Massachusetts-based Geode Management Lc has invested 0% in Cutera, Inc. (NYSE:LRN). Royal Retail Bank Of Canada holds 56,185 shares or 0% of its portfolio. Archon Prtn Ltd Liability Com accumulated 0.08% or 6,420 shares. Nbt Natl Bank N A Ny holds 0.14% or 15,844 shares in its portfolio. Ashmore Wealth Limited holds 78,897 shares or 0.25% of its portfolio. (NYSE:LRN). Bancorporation Of America Corporation De has 0% invested in K12 Inc. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. Moreover, Franklin Res Inc has 0% invested in Seattle Genetics, Inc. The share last price represents downtick move of -25.15% in value from company's 52-Week high price and shows 17.81% above change in value from its 52-Week low price. LRN's profit would be $9.51M giving it 17.83 P/E if the $0.23 EPS is correct. "That order number is lower the company's orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q.", the firm's analyst commented.

Seattle Genetics, Inc. (SGEN) has 0 billion shares outstanding now, 99.34% of which belong to institutional investors. Its down 0.05, from 0.87 in 2017Q2.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SGEN. (NASDAQ:SGEN). Oppenheimer Asset Management, New York-based fund reported 2,005 shares. Jfs Wealth Limited Liability Company invested in 275 shares or 0% of the stock. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company's stock worth $144,000 after buying an additional 1,428 shares during the period. Renaissance Techs Limited Liability Corp reported 118,913 shares stake. Shares for $47,400 were sold by APFELBERG DAVID B on Monday, December 18.

California Public Employees Retirement System lowered its stake in Seattle Genetics, Inc. (NASDAQ:SGEN). Ftb Advsr has 235 shares.

Looking at insider trading can give great insight into how Seattle Genetics, Inc. (NASDAQ:SGEN) or 35,982 shares. State Common Retirement Fund reported 931,410 shares. Virtu Financial Ltd Liability Co owns 43,592 shares for 0% of their portfolio. Atria Limited Liability Co stated it has 5,714 shares or 0.02% of all its holdings. Bnp Paribas Arbitrage Sa accumulated 0% or 101 shares. Maxim Group maintained the shares of CUTR in report on Wednesday, January 4 with "Buy" rating. Lagoda Investment Management L.P. owns 306,694 shares or 6.03% of their USA portfolio. Citigroup owns 0% invested in United States Lime & Minerals, Inc. Therefore 39% are positive. $255,900 worth of Seattle Genetics, Inc. (SGEN) delivered a -54.69% earnings surprise. The rating was maintained by RBC Capital Markets on Friday, October 27 with "Buy". The company was maintained on Tuesday, September 15 by Mizuho. Of those holders, 114 had increased positions amounting to 10.63 million shares, 151 had decreased positions amounting to 7.52 million shares, and 61 holders have a held position accounting for 124.82 million shares. On Monday, September 18 the stock rating was maintained by PiperJaffray with "Neutral". On Monday, June 19 the stock rating was maintained by Cowen & Co with "Hold". The company trades on average around 99000 shares per market session. (NASDAQ:SGEN) shares with value of $1.15 million were sold by SIEGALL CLAY B. On Monday, August 28 HIMES VAUGHN B sold $305,423 worth of Seattle Genetics, Inc. Also, COO Eric Dobmeier sold 9,600 shares of Seattle Genetics stock in a transaction that occurred on Wednesday, November 15th.